August 31, 2005 – This afternoon, the FDA is expected to issue its opinion on Dacogen, a treatment for myelodysplastic syndromes (MDS) that is the product of a partnership between SuperGen and MGI Pharma. MGI retains worldwide rights to the drug. In its Phase III trial, Dacogen produced significant improvements in its primary endpoints. We look at the drug and its mechanism plus we take a quick overview of recent developments at MGI Pharma...
